SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CBD Life Sciences Inc. – ‘1-A/A’ on 1/15/20

On:  Wednesday, 1/15/20, at 5:23pm ET   ·   Accession #:  1683168-20-147   ·   File #:  24-11005

Previous ‘1-A’:  ‘1-A/A’ on 10/17/19   ·   Next:  ‘1-A/A’ on 2/11/20   ·   Latest:  ‘1-A’ on 8/18/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/15/20  CBD Life Sciences Inc.            1-A/A                  3:1.7M                                   GlobalOne Filings Inc/FA

Pre-Qualification Amendment to Offering Statement — Reg. A   —   Form 1-A
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 1-A/A       Pre-Qualification Amendment to Offering Statement   HTML      8K 
                -- Reg. A -- primary_doc.xml                                     
 2: PART II AND III  Offering Statement - Parts II & III -- Reg. A  HTML    914K 
                - Form 1-A                                                       
 3: EX1A-12 OPN CNSL  Legal Opinion                                 HTML      8K 


‘1-A/A’   —   Pre-Qualification Amendment to Offering Statement — Reg. A — primary_doc.xml




        

This ‘1-A/A’ Document is an XML Data File that may be rendered in various formats:

  Form 1-A    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 

 
SEC Info rendering:  Pre-Qualification Amendment to Offering Statement
 
schemaVersion:

1-A: Filer Information

Issuer CIK
0001776073 
Issuer CCC
XXXXXXXX 
DOS File Number
 
Offering File Number
024-11005 
Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
Would you like a Return Copy? Checkbox not checked
Notify via Filing Website only? Checkbox not checked
Since Last Filing? Checkbox not checked

Submission Contact Information

Name
 
Phone
 
E-Mail Address
 

1-A: Item 1. Issuer Information

Issuer Infomation

Exact name of issuer as specified in the issuer's charter

CBD Life Sciences, Inc. 

Jurisdiction of Incorporation / Organization

NEVADA  

Year of Incorporation

1998 

CIK

0001776073 

Primary Standard Industrial Classification Code

RETAIL-MISCELLANEOUS RETAIL 

I.R.S. Employer Identification Number

20-5118532 

Total number of full-time employees

5 

Total number of part-time employees

0 

Contact Infomation

Address of Principal Executive Offices

Address 1

11445 E. VIA LINDA, UNIT 2-496 

Address 2

 

City

SCOTTSDALE 

State/Country

ARIZONA  

Mailing Zip/ Postal Code

85259 

Phone

480-776-0281 

Provide the following information for the person the Securities and Exchange Commission's staff should call in connection with any pre-qualification review of the offering statement.

Name

John E. Lux, Esq. 

Address 1

 

Address 2

 

City

 

State/Country

 

Mailing Zip/ Postal Code

 

Phone

 

Provide up to two e-mail addresses to which the Securities and Exchange Commission's staff may send any comment letters relating to the offering statement. After qualification of the offering statement, such e-mail addresses are not required to remain active.

Financial Statements

Use the financial statements for the most recent period contained in this offering statement to provide the following information about the issuer. The following table does not include all of the line items from the financial statements. Long Term Debt would include notes payable, bonds, mortgages, and similar obligations. To determine "Total Revenues" for all companies selecting "Other" for their industry group, refer to Article 5-03(b)(1) of Regulation S-X. For companies selecting "Insurance", refer to Article 7-04 of Regulation S-X for calculation of "Total Revenues" and paragraphs 5 and 7 of Article 7-04 for "Costs and Expenses Applicable to Revenues".

Industry Group (select one) Radio button not checked Banking Radio button not checked Insurance Radio button checked Other

Balance Sheet Information

Cash and Cash Equivalents

$ 26354.00 

Investment Securities
$ 0.00 
Total Investments

$  

Accounts and Notes Receivable

$ 148847.00 

Loans

$  

Property, Plant and Equipment (PP&E):

$ 0.00 

Property and Equipment

$  

Total Assets

$ 1484862.00 

Accounts Payable and Accrued Liabilities

$ 116470.00 

Policy Liabilities and Accruals

$  

Deposits

$  

Long Term Debt

$ 448110.00 

Total Liabilities

$ 564580.00 

Total Stockholders' Equity

$ 920282.00 

Total Liabilities and Equity

$ 1484862.00 

Statement of Comprehensive Income Information

Total Revenues

$ 63729.00 

Total Interest Income

$  

Costs and Expenses Applicable to Revenues

$ 488208.00 

Total Interest Expenses

$  

Depreciation and Amortization

$ 0.00 

Net Income

$ -638874.00 

Earnings Per Share - Basic

$ -0.02 

Earnings Per Share - Diluted

$ -0.02 

Name of Auditor (if any)

 

Outstanding Securities

Common Equity

Name of Class (if any) Common Equity

Common Stock, $0.001 par value 

Common Equity Units Outstanding

378341280 

Common Equity CUSIP (if any):

68403M200 

Common Equity Units Name of Trading Center or Quotation Medium (if any)

OTC Markets 

Preferred Equity

Preferred Equity Name of Class (if any)

Series A Non-Convertible 

Preferred Equity Units Outstanding

16081530 

Preferred Equity CUSIP (if any)

000000000 

Preferred Equity Name of Trading Center or Quotation Medium (if any)

none 

Debt Securities

Debt Securities Name of Class (if any)

not applicable 

Debt Securities Units Outstanding

0 

Debt Securities CUSIP (if any):

000000000 

Debt Securities Name of Trading Center or Quotation Medium (if any)

none 

1-A: Item 2. Issuer Eligibility

Issuer Eligibility

Check this box to certify that all of the following statements are true for the issuer(s)

Checkbox checked

  • Organized under the laws of the United States or Canada, or any State, Province, Territory or possession thereof, or the District of Columbia.
  • Principal place of business is in the United States or Canada.
  • Not subject to section 13 or 15(d) of the Securities Exchange Act of 1934.
  • Not a development stage company that either (a) has no specific business plan or purpose, or (b) has indicated that its business plan is to merge with an unidentified company or companies.
  • Not an investment company registered or required to be registered under the Investment Company Act of 1940.
  • Not issuing fractional undivided interests in oil or gas rights, or a similar interest in other mineral rights.
  • Not issuing asset-backed securities as defined in Item 1101 (c) of Regulation AB.
  • Not, and has not been, subject to any order of the Commission entered pursuant to Section 12(j) of the Exchange Act (15 U.S.C. 78l(j)) within five years before the filing of this offering statement.
  • Has filed with the Commission all the reports it was required to file, if any, pursuant to Rule 257 during the two years immediately before the filing of the offering statement (or for such shorter period that the issuer was required to file such reports).

1-A: Item 3. Application of Rule 262

Application Rule 262

Check this box to certify that, as of the time of this filing, each person described in Rule 262 of Regulation A is either not disqualified under that rule or is disqualified but has received a waiver of such disqualification.

Checkbox checked

Check this box if "bad actor" disclosure under Rule 262(d) is provided in Part II of the offering statement.

Checkbox not checked

1-A: Item 4. Summary Information Regarding the Offering and Other Current or Proposed Offerings

Summary Infomation

Check the appropriate box to indicate whether you are conducting a Tier 1 or Tier 2 offering Radio button checked Tier1 Radio button not checked Tier2
Check the appropriate box to indicate whether the financial statements have been audited Radio button checked Unaudited Radio button not checked Audited
Types of Securities Offered in this Offering Statement (select all that apply)
Checkbox checkedEquity (common or preferred stock) 

The information called for by this item below may be omitted if undetermined at the time of filing or submission, except that if a price range has been included in the offering statement, the midpoint of that range must be used to respond. Please refer to Rule 251(a) for the definition of "aggregate offering price" or "aggregate sales" as used in this item. Please leave the field blank if undetermined at this time and include a zero if a particular item is not applicable to the offering.

Price per security
$ 0.0050 
The portion of the aggregate offering price attributable to securities being offered on behalf of the issuer
$ 2000000.00 
The portion of the aggregate offering price attributable to securities being offered on behalf of selling securityholders
$ 0.00 
The portion of the aggregate offering price attributable to all the securities of the issuer sold pursuant to a qualified offering statement within the 12 months before the qualification of this offering statement
$ 0.00 
The estimated portion of aggregate sales attributable to securities that may be sold pursuant to any other qualified offering statement concurrently with securities being sold under this offering statement
$ 0.00 
Total (the sum of the aggregate offering price and aggregate sales in the four preceding paragraphs)
$ 2000000.00 

Anticipated fees in connection with this offering and names of service providers

Underwriters - Name of Service Provider
Underwriters - Fees
$  
Sales Commissions - Name of Service Provider
Sales Commissions - Fee
$  
Finders' Fees - Name of Service Provider
Finders' Fees - Fees
$  
Accounting or Audit - Name of Service Provider
Accounting or Audit - Fees
$  
Legal - Name of Service Provider
John E. Lux, Esq.
Legal - Fees
$ 25000.00 
Promoters - Name of Service Provider
Promoters - Fees
$  
Blue Sky Compliance - Name of Service Provider
Various states
Blue Sky Compliance - Fees
$ 2500.00 
CRD Number of any broker or dealer listed:
 
Estimated net proceeds to the issuer
$ 1920000.00 
Clarification of responses (if necessary)
 

1-A: Item 5. Jurisdictions in Which Securities are to be Offered

Jurisdictions in Which Securities are to be Offered

Using the list below, select the jurisdictions in which the issuer intends to offer the securities

Selected States and Jurisdictions

COLORADO
NEW YORK

Using the list below, select the jurisdictions in which the securities are to be offered by underwriters, dealers or sales persons or check the appropriate box

None Checkbox not checked
Same as the jurisdictions in which the issuer intends to offer the securities Checkbox checked
Selected States and Jurisdictions

COLORADO
NEW YORK

1-A: Item 6. Unregistered Securities Issued or Sold Within One Year

Unregistered Securities Issued or Sold Within One Year

None Checkbox not checked

Unregistered Securities Issued

As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

(a)Name of such issuer
CBD Life Sciences, Inc. 
(b)(1) Title of securities issued
Common Stock, $0.001 par value
 
(2) Total Amount of such securities issued
1458088
(3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
0 
(c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
550146
 
(2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
 

Unregistered Securities Act

(d) Indicate the section of the Securities Act or Commission rule or regulation relied upon for exemption from the registration requirements of such Act and state briefly the facts relied upon for such exemption
Sections 3(a)(10), 4(a)(1)
 

Top
Filing Submission 0001683168-20-000147   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 8:58:42.2am ET